Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib

摘要: A method of determining if a cancer patient is amenable to treatment with EGFR inhibitors including but not limited cetuximab, panitumumab or erlotinib by the following steps: (a) Obtaining cells from patient's tumor; (b) Determining said contain biomarker that predictive therapeutic response cetuximab panitumumab. The mutation status PIK3CA gene and expression PTEN gene. Tumors harbor activating mutations in Exon 9 20 which show loss protein will be considered likely benefit targeting therapies.